drugset
drugset / Trial / NCT04532931

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

NCT04532931 ↗

Phase 2 Completed 192 enrolled Shin Poong Pharmaceutical Co. Ltd. Medicines for Malaria Venture · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This exploratory study is a randomized, single center, open label study of four different experimental treatment arms versus standard of care for the treatment of SARS-CoV-2 infection in symptomatic outpatients with mild disease at the time of enrollment.

Timeline

Start
2020-09-03
Primary completion
2021-08-05
Completion
2021-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 180 mg Oral
Subject Artesunate Small molecule 200 mg Oral
Subject Artesunate Small molecule 240 mg Oral
Subject Daclatasvir Small molecule 60 mg Oral
Subject Favipiravir Small molecule 600 mg Oral
Subject Nitazoxanide Other / unclassified 1000 mg Oral
Subject Pyronaridine Unknown 540 mg Oral
Subject Pyronaridine Unknown 720 mg Oral
Subject Sofosbuvir Small molecule 400 mg Oral
Subject amodiaquine Other / unclassified 540 mg Oral
Comparator Acetaminophen Small molecule 1000 mg Oral

Indications

COVID-19